Alzheimer Disease pp 367-372 | Cite as
Anapsos: New Therapeutic Strategies for Neurodegeneration and Brain Aging with Neuroimmunotrophic Factors
Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by an heterogeneous etiopathogenesis on a genetic basis. The most prominent neuropathological findings in AD are senile plaques, neurofibrillary tangles (NFT), amyloid deposition in neural tissues and vessels, synaptic loss and subsequent neuronal death (Cacabelos et al., 1993, 1995; Hardy and Allsop, 1991; Terry et al., 1991). However, other neurochemical mechanisms may also account for cell death and neurodegeneration in AD, including neuroimmune dysfunction, free radical formation, neurotransmitter deficits and alterations in brain calcium homeostasis (Cacabelos et al., 1994, 1995; Richardson, 1993). So, new approaches to AD treatment are oriented to search for agents acting on etiopathogenic events and pleiotropic compounds displaying multifactorial effects.
Keywords
Atopic Dermatitis Ibotenic Acid Passive Avoidance Behavior Brain Histamine Hippocampal NeurodegenerationPreview
Unable to display preview. Download preview PDF.
References
- Alvarez XA, Zas R, Lagares R, Franco A, Maneiro E, Miguel-Hidalgo JJ, Lao JI, Fernandez-Novoa L, Diaz J and Cacabelos R (1995): Neuroinmunomodulatory and neurotrophic activity of anapsos: Studies with laboratory animals. Ann Psychiatry 5:267–280.Google Scholar
- Cacabelos R, Alvarez XA, Fernandez-Novoa L, Franco A, Mangues R, Pellicer A and Nishimura T (1994): Brain Interleukin-16 in Alzheimer’s disease and vascular dementia. Meth Find Exp Clin Pharmacol 16:141–151.Google Scholar
- Cacabelos R, Hofman A, Mullan M, Ferris SH, Portera A, Frey H, Swaab DF, de Leon M, Terry R, Masters CL, Iqbal K, Wisniewski HM, Takeda N, Giacobini E, Nordberg A and Winblad B (1993): Alzheimer’s disease: Scientific progress for future trends. DN&P 6:242–244.Google Scholar
- Cacabelos R, Nordberg A, Caamano J, Franco-Maside A, Fernandez-Novoa L, Gomez MJ, Alvarez XA, Takeda M, Prous J Jr, Nishimura T and Winblad B (1995): Therapeutic strategies in Alzheimer’s disease. Ann Psychiatry 4: 221–279.Google Scholar
- Hardy J and Allsop D (1991): Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trend Pharmacol Sci 12:383–388.CrossRefGoogle Scholar
- Horvath A, Alvarado F, Szocs J, De Alvarado ZN and Padilla G (1967): Metabolic effects of Calagualine, an antitumoral saponine of Polypodium Leucotomos. Nature 214:1256–1258.PubMedCrossRefGoogle Scholar
- Richardson JS (1993): Free radicals in the genesis of Alzheimer’s disease. Ann NY Acad Sci 695:73–76.PubMedCrossRefGoogle Scholar
- Terry RD, Masliah E, Salmon DP, Butters N, De Teresa R, Hill R, Hansen LA and Katzman R (1991): Physical basis of cognitive alterations in Alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572–80.PubMedCrossRefGoogle Scholar
- Tuominen M, Bohlin L, Lindbom L-O and Rolfsen W (1991): Enhancing effect of Calaguala on the prevention of rejection on skin transplants in mice. Phytotherapy Res 5:234–236.CrossRefGoogle Scholar
- Vargas J, Muñoz C, Osorio C and García-Olivares E (1983): Anapsos, an antipsoriatic drug which increases the proportion of suppressor cells in human peripheral blood. Ann Immunol 134:393–400.Google Scholar